Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2026

Stockholders' Equity Note [Abstract]

Schedule of Designated Preferred Shares

As of March 31, 2026, the Company has designated the following preferred stock:

Designated Preferred Shares	March 31, 2026
Series A	4,200
Series B	2,360
Series C	590
Series D	10,000
Series E	40,000
Series E-1	12,960
Series F-1	24,900
Series F-2	24,900
Series F-3	34,860
Series F-4	24,900
Total	179,670

Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model

The Company values stock options using the Black-Scholes option pricing model and used the following assumptions, on a weighted-average basis, during the reporting periods:

	Three Months Ended March 31,
	2026	2025
Expected terms (years)	5.7	5.7
Expected volatility	70.5%	90.0%
Risk-free interest rate	3.73%	4.35%
Expected dividends	0.00%	0.00%

Schedule of Stock Option Activity

The following is a summary of stock option activity for the three months ended March 31, 2026:

	Number of Options	Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)
Outstanding at January 1, 2026	7,785,149	$	10.05	7.8	$	17,391
Granted	922,369	9.40		9.8
Exercised	(43,431)	5.30
Expired	(2,583)	16.25
Cancelled/Forfeited	(40,874)	10.82
Outstanding at March 31, 2026	8,620,630	$	10.00	7.7	$	13,933
Exercisable at March 31, 2026	5,416,653	$	9.00	7.0	$	11,392
Unvested at March 31, 2026	3,203,977	$	11.69	9.0	$	2,541

Schedule of Restricted Stock Units Granted

The following tables include information for all restricted stock units granted including inducement grants that are granted outside of the 2020 Plan.

	Number of Restricted Stock Units	Weighted Average Grant Date Fair Value
Outstanding at January 1, 2026	—	$	—
Granted	914,477	9.41
Vested	—	—
Forfeited	(7,311)	9.40
Outstanding at March 31, 2026	907,166	$	9.41

Schedule of Recognized Share-based Compensation Cost

The following is a summary of share-based compensation expense in the statement of operations:

	Three Months Ended March 31,
(In thousands)	2026		2025
Selling, general and administrative	$	3,162	$	4,529
Research and development	1,386		1,568
Cost of goods sold	398		766
Total	$	4,946	$	6,863

Schedule of Warrant Activity

The following is a summary of common stock warrant activity for the three months ended March 31, 2026:

	Warrants	Weighted Average Exercise Price
Outstanding at January 1, 2026	1,341,375	$	0.01
Warrants issued	—	—
Warrants exercised	—	—
Warrants canceled	—	—
Outstanding and exercisable at March 31, 2026	1,341,375	$	0.01

Schedule of Information Related to Stock Warrants Outstanding and Exercisable

The following table presents information related to common stock warrants outstanding at March 31, 2026:

	Warrants Exercisable
Range of Exercise Prices	Outstanding Number of Warrants	Weighted Average Remaining Warrant Term (in years)
$0.01 (1)	1,341,375	n/a

(1) Pre-funded warrants with a $0.01 exercise price do not expire until exercised.